Date: 2017-04-18
Type of information: Construction of new premises
Compound:
- UK viral vector manufacturing capabilities and Sweden DNA plasmid production and characterisation capabilities
Company: Cobra Biologics (Sweden)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details:
- • On April 18, 2017, Cobra Biologics announced it is to expand operations at its sites in UK and Sweden to meet the increased demand of gene and immunotherapy companies to fast track their portfolios through to in-market supply.
- Over the next two years Cobra will invest up to £15m (165m SEK) on a phased expansion plan, supporting the company’s R&D expertise in developing rapid and cost effective viral vector and DNA plasmid production platforms. The initial phase, will be in the UK and will extend the company’s viral vector Phase III and commercial manufacturing capabilities to support more customers to rapidly advance their products through clinical trials to in-market supply. The second phase, in Sweden, will double capacity for High Quality (HQ) DNA plasmid production and characterisation, essential for supporting early clinical phase Adeno-associated virus (AAV) and lentivirus manufacture being used by pioneering CAR T-cell therapy companies targeting acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia.
- The third phase of investment will see the addition of larger clinical and commercial capabilities for GMP DNA production. In total, it is anticipated these investments will create up to 50 new jobs, in addition to the 135 jobs already created in the UK and Sweden since 2011 and will also benefit the wider supply chain companies which provide Cobra with services and facilities.
Financial terms:
Latest news:
Is general: Yes
